Biomarkers and Outcomes in the Diabetes Prevention Program

糖尿病预防计划中的生物标志物和结果

• 批准号: 7610881
• 负责人: Ronald B Goldberg
• 金额: $ 49.71万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7610881
• 关键词: Ankle; Apolipoproteins B; Biological Markers; Blood Pressure; Blood Vessels; Blood specimen; Body Weight; Body Weight decreased; Body fat; CCL2 gene; Chronic Disease; Coagulants; Coagulation Process; Complications of Diabetes Mellitus; Controlled Clinical Trials; Coronary heart disease; Development; Diabetes Mellitus; Diabetic Angiopathies; Diagnosis; Diet; Disease; Disease Pathway; E-Selectin; Economic Burden; Equilibrium; Fibrinogen; Follow-Up Studies; Functional disorder; Glucose; Goals; Health; Individual; Inflammation; Intercellular adhesion molecule 1; Interleukin-6; Intervention; Kidney Diseases; Leptin; Life Style; Lipids; Long-Term Effects; Measurement; Measures; Mediator of activation protein; Metabolic; Metabolic Marker; Metabolic syndrome; Metformin; Methods; Morbidity - disease rate; Myocardial Infarction; Neuropathy; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Outcome; Outcome Study; Pathway interactions; Peripheral Vascular Diseases; Persons; Physical activity; Placebos; Plasminogen Activator Inhibitor 1; Predictive Value; Prevention; Process; Randomized Clinical Trials; Resistance; Retinal Diseases; Risk; Risk Factors; Role; Stroke; Testing; Thick; Time; Translating; Visit; adiponectin; cohort; design; diabetes prevention program; disorder risk; economic impact; effective intervention; follow-up; health economics; high risk; improved; indexing; inflammatory marker; insulin secretion; insulin sensitivity; intervention effect; intima media; lifestyle intervention; macrovascular disease; novel; post gamma-globulins; prevent; therapeutic target; treatment effect

DESCRIPTION (provided by applicant): Despite advances in the treatment of type 2 diabetes and its Complications, the health impact and economic burden of diabetes continues to expand. The Diabetes Prevention Program (DPP) identified persons at high risk for diabetes and showed that lifestyle and pharmacologic intervention strategies were effective in preventing or delaying the development of diabetes; ongoing studies in the DPP Outcome Study (DPPOS) are examining the long-term impact of these interventions. This proposal is aimed at assessing novel biomarker levels in DPP and DPPOS. These biomarkers reflect pathophysiological pathways considered important in the development of diabetes and its vascular complications in a longitudinal manner, building on the current design of DPP/DPPOS. Using stored blood samples at the baseline and 1-year DPP time points and at entry into DPPOS, the specific aims of this projects are to investigate (1) The effects of interventions on biomarkers (2) Biomarker prediction and intervention effects on development of diabetes, and its co-morbidities (3) Baseline biomarkers and prediction of microvascular and macrovascular complications of diabetes (4) Biomarker levels at diabetes onset and prediction of complications. Biomarkers of inflammation (CRP, IL-6, MCP-1, TNFalpha), coagulant balance (PAI-1, fibrinogen, tPA), endothelial dysfunction (sICAM-1, sVCAM-1, E-selectin) and of metabolic deregulation (adiponectin, apo B, leptin) and cystatin C have been selected for measurement. Change in biomarker levels from DPP baseline to 1 year will assess effects of interventions on biomarkers, and all three biomarker assessments, reflecting pre-intervention, 1-year on-treatment and longer-term on-treatment effects will determine the predictive value of biomarkers on development of diabetes and its complications. Circulating biomarkers of inflammation, coagulation and vascular dysfunction are increasingly being shown to provide a measure of the role of these processes in chronic diseases. This proposal will provide novel information on the disease pathways involved in the development of diabetes and its complications in subjects at high risk for this disease and thereby create improved opportunities for prediction and methods of treatment in the development of type 2 diabetes and its complications.

描述（由申请人提供）：尽管治疗2型糖尿病及其并发症的进展，但糖尿病的健康影响和经济负担仍在不断扩大。糖尿病预防计划（DPP）确定了患有糖尿病高风险的人，并表明生活方式和药物干预策略有效地预防或延迟糖尿病的发展； DPP结果研究（DPPO）正在进行的研究正在研究这些干预措施的长期影响。该建议旨在评估DPP和DPPO中的新生物标志物水平。这些生物标志物反映了被认为在纵向方式以DPP/DPPO的设计为基础的纵向方式的病理生理途径中被认为在糖尿病及其血管并发症中重要的重要。在基线和1年DPP时间点以及进入DPPO时使用储存的血液样本，该项目的具体目的是调查（1）干预措施对生物标志物（2）生物标志物（2）生物标志物和干预对糖尿病的发展的影响，对糖尿病的发育及其共同膜的预测（3）基线生物标志和预测的生物症状和临床（4）的糖尿病和临床（4）的糖尿病性（4）（4）的糖尿病性（4）（4）的糖尿病性（4）（4）（4）氧化和预测（4）的糖尿病性（4）（4）含量（4）临床（4）。糖尿病发作和并发症的预测。炎症的生物标志物（CRP，IL-6，MCP-1，TNFALPHA），凝结剂平衡（PAI-1，纤维蛋白原，TPA），内皮功能障碍（SICAM-1，SVCAM-1，E-塞氏菌）和代谢性抑制（脂肪核定蛋白，Apo b，apo b，cyertin cyertin cytation and cyertin cy forebolic be）从DPP基线到1年的生物标志物水平的变化将评估干预措施对生物标志物的影响，以及所有三种生物标志物评估，反映了干预前，1年的现场治疗和长期治疗效应将确定生物标志物在糖尿病及其并发症的发展中的预测价值。越来越多地证明循环炎症，凝结和血管功能障碍的生物标志物提供了这些过程在慢性疾病中的作用的量度。该提案将提供有关糖尿病发展及其在这种疾病高风险的受试者中涉及的疾病途径的新信息，从而为2型糖尿病及其并发症的发展提供了改善的预测和治疗方法的机会。